{"nctId":"NCT02474589","briefTitle":"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat","startDateStruct":{"date":"2015-06-19","type":"ACTUAL"},"conditions":["Smallpox"],"count":449,"armGroups":[{"label":"Active","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tecovirimat"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"tecovirimat","otherNames":["ST-246"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 80 years old, inclusive\n* Available for clinical follow-up for the duration of the study\n* Able and willing to give informed consent\n* In good general health without clinically significant medical history; not have been hospitalized for a chronic medical condition for the last 2 years\n* Able to comply with dietary requirements throughout the study drug dosing period\n* Adequate venous access for those individuals participating in PK testing\n* PE and laboratory results without clinically significant findings within the 14 days before receipt of study drug\n* Agree not to drink alcohol from the beginning of the Screening Period through the completion of the Day 28 Follow up Visit\n* Agree not to use any nicotine products, including electronic vapor cigarettes, nicotine patches or nicotine gum for at least 30 days before the Day 1 Visit and through completion of the Day 15 Dosing complete Visit\n* Agree not to consume caffeine during all study visits, including overnight stays if participating in PK subset\n* Agree not to receive any immunizations/vaccinations\n* Agree not to take herbal products\n* Able and willing to refrain from taking any prescriptions and nonprescription medications with exceptions\n* For women of childbearing potential, negative serum and urine pregnancy testing\n* If male, agree not to donate sperm\n* Meet 1 of the following criteria: The subject or their partner has undergone surgical sterilization; the subject is postmenopausal; the subject agrees to be abstinent; the subject agrees to consistently use a method of approved birth control.\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding or planning pregnancy\n* Have a history of any clinically significant conditions\n* Have any limitation of activity related to cardiac disease\n* Have a bleeding disorder diagnosed by a doctor, or a history of significant bruising or bleeding with intramuscular injections or blood draws\n* Currently using certain medications\n* Have a malignancy that is active or a treated malignancy for which there is no reasonable assurance of sustained cure, or malignancy that is likely to recur during the study\n* Have a history of seizure\n* Have a clinically significant blood dyscrasia\n* Have a history of drug allergy that contraindicates participation in the trial\n* Have a medical, psychiatric, or social condition or any occupational reason, or other responsibility that in the judgment of the investigator would render the subject unable to comply with the protocol\n* Have an inability to swallow medication\n* Have a clinically significant abnormal ECG\n* Have participated in a clinical trials within 30 days of study entry or planning to participate in any experimental treatment study during the study period\n* Have a history or current drug or alcohol abuse\n* Have received immunizations/vaccines\n* Have a current clinically significant acute bacterial, fungal, or mycobacterial infection requiring administration of systemic antibiotics\n* Have known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection with the exception of clinically significant dermal infections\n* Have known hepatitis B or C infection, or positive test result\n* Have known HIV infection or AIDS or a positive test for HIV\n* Have a current clinically significant viral infection\n* Have known clinically significant chronic viral infection\n* have received treatment with greater than 20 mg prednisone or equivalent dose or any immunosuppressant or immunomodulary medication\n* Have abnormal laboratory testing during screening\n* Have a greater than or equal than 20% risk of suffering a major cardiovascular event\n* Have been previously enrolled in this or any clinical trial involving tecovirimat","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Determine the Number of Participants With Adverse Events","description":"To determine the safety and tolerability of oral tecovirimat","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":359},"commonTop":["Headache","Nausea","Diarrhoea","Dizziness","Fatigue"]}}}